CXL

DRUG3 trials

Sponsors

Rush Eye Associates, Pfizer, Farabi Eye Hospital

Conditions

CAZ-AVICXLCorneal Ectasia Disorders Including KeratoconusEffect on Intestinal FloraOpen LabelPharmacokineticsSafetyTreatment

Phase 1

A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers

CompletedNCT01789528

PfizerCAZ-AVI, CXL, Effect on Intestinal Flora +3

Start: 2013-08-31End: 2014-03-31Updated: 2017-09-05

Phase 3

The Effects of Corneal Collagen Cross-linking

Rush Eye AssociatesCorneal Ectasia Disorders Including Keratoconus

Start: 2012-10-31End: 2024-10-31Target: 30Updated: 2022-10-26

Unknown Phase

UVX as an Adjuvant in the Treatment of Fungal Keratitis

Farabi Eye HospitalTreatment

Start: 2015-01-01End: 2017-07-01Updated: 2017-05-03

Related Papers

Epithelium-off versus transepithelial corneal collagen crosslinking for progressive corneal ectasia: a randomised and controlled trial

British Journal of Ophthalmology2016-07-0734 citations